Erratum: "A novel model of SCID-X1 reconstitution reveals predisposition to retrovirus-induced lymphoma but no evidence of γC gene oncogenicity" (Molecular Therapy (2009) vol. 17 (1031-1038) 10.1038/mt.2009.59);A novel model of SCID-X1 reconstitution reveals predisposition to retrovirus-induced lymphoma but no evidence of γC gene oncogenicity

Molecular Therapy

Volumn 17, Issue 6, 2009, Pages 1031-1038

  Scobie, Linda ^a,b   Hector, Ralph D ^a,b   Grant, Louise ^a   Bell, Margaret ^a   Nielsen, Anne A ^a   Meikle, Sharon ^a   Philbey, Adrain ^a   Thrasher, Adrain J ^c   Cameron, Ewan R ^a   Blyth, Karen ^a   Neil, James C ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b GLASGOW CALEDONIAN UNIVERSITY   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2 RECEPTOR GAMMA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CANCER SUSCEPTIBILITY; CD8+ T LYMPHOCYTE; CELL ISOLATION; CELL MATURATION; CONTROLLED STUDY; GENE EXPRESSION; GENE LOCUS; IMMUNOPHENOTYPING; LEUKEMOGENESIS; LYMPHOCYTE SUBPOPULATION; LYMPHOMA; MEMBRANE RECONSTITUTION; MOUSE; MUTAGENESIS; NONHUMAN; ONCOGENE; PHENOTYPE; PROMOTER REGION; T LYMPHOCYTE; TRANSGENE; TRANSGENIC MOUSE; VIRUS STRAIN; X LINKED SEVERE COMBINED IMMUNODEFICIENCY;

MURINE LEUKEMIA VIRUS; MUS; MUS MUSCULUS;

EID: 67349162619     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2009.117     Document Type: Erratum

References (45)

1. Cavazzana-Calvo, M, Hacein-Bey, S, de Saint Basile, G, Gross, F, Yvon, E, Nusbaum, P et al. (2000). Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288: 669-672.
2. Deichmann, A, Hacein-Bey-Abina, S, Schmidt, M, Garrigue, A, Brugman, MH, Hu, J et al. (2007). Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. J Clin Invest 117: 2225-2232.
3. Schwarzwaelder, K, Howe, SJ, Schmidt, M, Brugman, MH, Deichmann, A, Glimm, H et al. (2007). Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo. J Clin Invest 117: 2241-2249.
4. Hacein-Bey-Abina, S, von Kalle, C, Schmidt, M, Le Deist, F, Wulffraat, N, McIntyre, E et al. (2003). A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 348: 255-256.
5. Rabbitts, TH, Bucher, K, Chung, G, Grutz, G, Warren, A and Yamada, Y (1999). The effect of chromosomal translocations in acute leukemias: The LMO2 paradigm in transcription and development. Cancer Res 59 1794s-1798s.
6. Cornetta, K, Morgan, RA and Anderson, WF (1991). Safety issues related to retroviral-mediated gene transfer in humans. Hum Gene Ther 2 5-14.
7. Belmont, JW (1995). Insights into lymphocyte development from X-linked immune deficiencies. Trends Genet 11: 112-116.
8. Uribe, L and Weinberg, KI (1998). X-linked SCID and other defects of cytokine pathways. Semin Hematol 35: 299-309.
9. Mertsching, E, Meyer, V, Linares, J, Lombard-Platet, S and Ceredig, R (1998). Interleukin-7, a non-redundant potent cytokine whose over-expression massively perturbs B-lymphopoiesis. Int Rev Immunol 16: 285-308.
10. Soudais, C, Shiho, T, Sharara, LI, Guy-Grand, D, Taniguchi, T, Fischer, A et al. (2000). Stable and functional lymphoid reconstitution of common cytokine receptor γ chain deficient mice by retroviral-mediated gene transfer. Blood 95: 3071-3077.
11. Dave, UP, Jenkins, NA and Copeland, NG (2004). Gene therapy insertional mutagenesis insights. Science 303: 333.
12. Woods, NB, Bottero, V, Schmidt, M, von Kalle, C and Verma, IM (2006). Therapeutic gene causing lymphoma. Nature 440: 1123.
13. + cells: implications for leukemogenesis in gene therapy. Leukemia 21 754-763.
14. Greaves, DR, Wilson, FD, Lang, G and Kioussis, D (1989). Human CD2 3′-flanking sequences confer high-level T cell-specific, position-independent gene expression in transgenic mice. Cell 56: 979-986.
15. Stewart, MA, Cameron, E, Toth, S, Campbell, M, McFarlane, R, Onions, D et al. (1993). Conditional expression and oncogenicity of a human c-myc transgene linked to a human CD2 dominant control region. Int J Cancer 53: 1023-1030.
16. Badiani, PA, Kioussis, D, Swirsky, DM, Lampert, TA and Weston, K (1996). T-cell lymphomas in v-myb transgenic mice. Oncogene 13: 2205-2212.
17. Karsunky, H, Geisen, C, Schmidt, T, Haas, K, Zevnik, B, Gau, E et al. (1999). Oncogenic potential of cyclin E in T-cell lymphomagenesis in transgenic mice: Evidence for cooperation between cyclin E and Ras but not Myc. Oncogene 18: 7816-7824.
18. Vaillant, F, Blyth, K, Terry, A, Bell, M, Cameron, E, Neil, J et al. (1999). A full length Cbfa1 gene product perturbs T-cell development and promotes lymphomagenesis in synergy with MYC. Oncogene 18 7124-7134.
19. Turner, SD, Merz, H, Yeung, D and Alexander, DR (2006). CD2 promoter regulated nucleophosmin-anaplastic lymphoma kinase in transgenic mice causes B lymphoid malignancy. Anticancer Res 26: 3275-3279.
20. van Hamburg, JP, de Bruijn, MJ, Dingjan, GM, Beverloo, HB, Diepstraten, H, Ling, KW et al. (2008). Cooperation of Gata3c-Myc and Notch in malignant transforamtion of double postivie thymocytes. Mol Immunol 45: 3085-3095.
21. Bernard, O, Cory, S, Gerondakis, S, Webb, E and Adams, JM (1983). Sequence of the murine and human cellular myc oncogenes and two modes of myc transcription resulting from chromosome translocation in B lymphoid tumours. EMBO J 2: 2375-2383.
22. van Lohuizen, M, Verbeek, S, Krimpenfort, P, Domen, J, Saris, C, Radaszkiewicz, T et al. (1989). Predisposition to lymphomagenesis in pim-1 transgenic mice: Cooperation with c-myc and N-myc in murine leukemia virus-induced tumors. Cell 56: 673-682.
23. Blyth, K, Terry, A, Mackay, N, Vaillant, F, Cameron, E, Neil, JC et al. (2001). Runx2: A novel oncogenic effector revealed by in vivo complementation and retroviral tagging. Oncogene 20: 295-302.
24. Uren, AG, Kool, J, Berns, A and van Lohuizen, M (2005). Retroviral insertional mutagenesis: Past, present and future. Oncogene 24 7656-7672.
25. Fan, H (1997). Leukemogenesis by Moloney murine leukemia virus: A multistep process. Trends Microbiol 5: 74-82.
26. de Boer, J, Williams, A, Skavdis, G, Harker, N, Coles, M, Tolaini, M et al. (2003). Transgenic mice with hematopoietic and lymphoid specific expression of Cre. Eur J Immunol 33: 314-325.
27. Jonkers, J and Berns, A (1996). Retroviral insertional mutagenesis as a strategy to identify cancer genes. Biochim Biophys Acta 1287 29-57.
28. Stewart, MA, Terry, A, O'Hara, M, Cameron, ER, Onions, DE and Neil, JC (1996). Til-1, a novel insertion locus for Moloney murine leukaemia virus in lymphomas of CD2-myc transgenic mice. J Gen Virol 77 443-446.
29. Blyth, K, Terry, A, O'Hara, M, Baxter, EW, Campbell, M, Stewart, M et al. (1995). Synergy between a human c-myc transgene and p53 null genotype in murine thymic lymphomas: Contrasting effects of homozygous and heterozygous p53 loss. Oncogene 10: 1717-1723.
30. Donehower, LA, Harvey, M, Slagle, BL, McArthur, MJ, Montgomery, CA, Butel, JS et al. (1992). Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356: 215-221.
31. Blyth, K, Stewart, M, Bell, M, James, C, Evan, G, Neil, JC et al. (2000). Sensitivity to Myc-induced apoptosis is retained in spontaneous and transplanted lymphomas of CD2-mycER mice. Oncogene 19: 773-782.
32. Disanto, JP, Müller, W, Guy-grand, D, Fischer, A and Rajewsky, K (1995). Lymphoid development in mice with a targeted deletion of the interleukin-2 receptor γ chain. Proc Natl Acad Sci USA 92: 377-381.
33. Schuringa, JJ, Chung, KY, Morrone, G and Moore, MA (2004). Constitutive activation of STAT5A promotes human hematopoietic stem cell self-renewal and erythroid differentiation. J Exp Med 200: 623-635.
34. Disanto, JP, Guygrand, D, Fisher, A and Tarakhovsky, A (1996). Critical role for the common cytokine receptor γ chain in intrathymic and peripheral T cell selection. J Exp Med 183: 1111-1118.
35. Thrasher, AJ, Gasper, HB, Baum, C, Modlich, U, Schambach, A, Candotti, F et al. (2006). Gene therapy: X-SCID transgene leukaemogenicity. Nature 443: E5-E6.
36. Hacein-Bey-Abina, S, Garrigue, A, Wang, GP, Soulier, J, Lim, A, Morillon, E et al. (2008). Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 118: 3132-3142.
37. Howe, SJ, Mansour, MR, Schwarzwaelder, K, Bartholomae, C, Hubank, M, Kempski, H et al. (2008). Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 118: 3143-3150.
38. Kim, S, Xu, X, Hecht, A and Boyer, TG (2006). Mediator is a transducer of Wnt/β-catenin signaling. J Biol Chem 281: 14066-14075.
39. Neil, JC and Cameron, ER (2002). Retroviral insertion sites and cancer: Fountain of all knowledge? Cancer Cell 2: 253-255.
40. Shou, Y, Ma, ZJ, Lu, T and Sorrentino, BP (2006). Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapy. Proc Natl Acad Sci USA 103: 11730-11735.
41. Baum, C, Kustikova, O, Modlich, U, Li, ZX and Fehse, B (2006). Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors. Hum Gene Ther 17: 253-263.
42. Zhang, F, Thornhill, SI, Howe, SJ, Ulaganathan, M, Scharnbach, A, Sinclair, J et al. (2007). Lentiviral vectors containing an enhancer-less ubiquitously acting chromatin opening element (UCOE) provide highly reproducible and stable transgene expression in hematopoietic cells. Blood 110: 1448-1457.
43. Zhumabekov, T, Corbella, P, Tolaini, M and Kioussis, D (1995). Improved version of a human CD2 minigene based vector for T cell-specific expression in transgenic mice. J Immunol Methods 185: 133-140.
44. Hogan, B, Beddington, R, Constantini, F and Lacey, E (1994). Manipulating the Mouse Embryo: A Laboratory Manual, 2nd edn. Cold Spring Harbot Laboratory Publications: New York.
45. Goldman, JP, Blundell, MP, Lopes, L, Kinnon, C, Di Santo, JP and Thrasher, AJ (1998). Enhanced human cell engraftment in mice deficient in RAG2 and the common cytokine receptor γ chain. Br J Haematol 103: 335-342.